MedPath

Bio-Path Holdings Advances Cancer Therapies with Clinical Trial Progress and $4 Million Funding

• Bio-Path Holdings has secured $4 million in private placement to bolster its financial position for advancing clinical trials of its cancer treatments. • Prexigebersen, Bio-Path's lead candidate, has completed Phase 1 trials for AML and is in Phase 2 trials, with potential applications in obesity-related cancers. • BP1001-A, an enhanced version of prexigebersen, has begun Phase 1 trials for solid tumors, demonstrating a favorable safety profile in higher dose cohorts. • BP1003 is in pre-clinical development for pancreatic cancer, showing success in penetrating pancreatic tumors, highlighting Bio-Path's commitment to addressing multiple cancer types.

Bio-Path Holdings, Inc. (Nasdaq:BPTH) has announced significant progress in its clinical trials and secured $4 million in funding through a private placement, according to Stonegate Capital Partners. The funding aims to support the biotechnology company's operational plans in developing innovative cancer treatments.

Prexigebersen Clinical Trials

Bio-Path's lead candidate, prexigebersen, has completed Phase 1 clinical trials for acute myeloid leukemia (AML) and other blood cancers. It is currently undergoing Phase 2 trials for AML. The company is also exploring prexigebersen's potential in treating obesity and obesity-related cancers, expanding its market reach.

Advancing Pipeline Candidates

BP1001-A, an enhanced version of prexigebersen, has entered Phase 1 trials for solid tumors, with the first patient treated in a higher dose cohort. The drug has demonstrated a favorable safety profile. BP1002 is in two separate Phase 1 clinical trials: one for advanced lymphoid malignancies and another for refractory/relapsed AML patients, including those relapsed from venetoclax-based treatment. The second dose cohort in the latter trial has been completed.

Pre-clinical Development of BP1003

BP1003 is in pre-clinical development for pancreatic cancer, demonstrating success in penetrating pancreatic tumors in previous trials. This highlights Bio-Path’s commitment to addressing various cancer types and stages.

DNAbilize® Technology

At the core of Bio-Path’s technology is DNAbilize®, a proprietary antisense and liposome delivery platform for DNA drugs. This approach aims to overcome challenges associated with traditional delivery methods, potentially reducing side effects. The technology's broad applicability positions Bio-Path as a potentially disruptive force in the biopharmaceutical industry.

Strategic Partnerships and Intellectual Property

Bio-Path has strategic relationships with The MD Anderson Cancer Center and other leading cancer centers, providing collaborative opportunities and access to clinical trial sites. The company's intellectual property includes composition of matter and method patents for antisense targets and manufacturing, creating barriers to entry for competitors.

Financial Position

While Bio-Path reported $0.6 million in cash on hand as of September 30, 2024, the recent $4 million private placement, closed on October 10, 2024, extends the company’s cash runway. This funding supports ongoing clinical trials and pipeline advancement.
Stonegate Capital Partners suggests that Bio-Path Holdings may be undervalued compared to its peers, considering its multiple drug candidates and approaching Phase 2 milestones for prexigebersen. Regulatory approval could significantly impact the company’s valuation.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

BiPER Therapeutics Secures €800,000 to Advance BiP Inhibitor for Gastrointestinal Cancers

BiPER Therapeutics has secured €800,000 in bridge funding to advance its lead candidate, BPR001-615, a first-in-class BiP inhibitor, towards clinical trials.
The funding will support the completion of regulatory toxicology studies and preparation for Phase 1/2a clinical trial applications in Europe and the US.

Oncolytics Biotech and Bio-Path Holdings Announce Promising Cancer Therapy Advancements

Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.
A GOBLET study cohort showed a 33% objective response rate in relapsed anal cancer patients treated with pelareorep and atezolizumab, including a complete response lasting over 15 months.

Vectus Biosystems Advances Clinical Trials and Commercialization Efforts

Vectus Biosystems is actively progressing its clinical trials, marking a significant step in its drug development pipeline.
The company is also focusing on commercialization strategies to bring its innovative therapies to market effectively.

Allarity Therapeutics' Stenoparib Shows Promise in Advanced Ovarian Cancer Phase 2 Trial

Allarity Therapeutics reports that two patients with advanced ovarian cancer have remained on stenoparib treatment for over 14 months in a Phase 2 trial.
The company's strong financial position, with $18.5 million in cash, supports the advancement of stenoparib towards potential FDA registration.

Bio-Path Holdings Expands DNAbilize Platform into Obesity and Advances Oncology Programs

Bio-Path Holdings initiated a therapeutic program, BP1001-A, for obesity and related metabolic diseases, marking the first non-cancer application of its DNAbilize® technology.
The company completed enrollment for the third dosing cohort of its Phase 1/1b clinical trial of BP1002 in venetoclax-resistant AML patients, ahead of schedule.

MB-105, a CD5-Targeted CAR-T Cell Therapy, Receives FDA Orphan Drug Designation for T-Cell Lymphoma

March Biosciences' MB-105, a first-in-class CD5 CAR-T cell therapy, has received FDA Orphan Drug Designation for relapsed/refractory CD5-positive T-cell lymphoma.
The Orphan Drug Designation provides incentives including tax credits, user fee exemptions, and seven years of market exclusivity post-approval.

Avidity Biosciences Initiates Biomarker Cohort in Phase 1/2 FORTITUDE Trial for FSHD Therapy

Avidity Biosciences has commenced enrollment for Cohort C of the Phase 1/2 FORTITUDE trial, evaluating delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) patients.
The biomarker cohort will assess the impact of del-brax (2 mg/kg every six weeks) on DUX4-regulated biomarkers in FSHD patients aged 16-70, across US, Canada, and the UK.

£400M Investment to Establish Clinical Trial Hubs Across the UK

A £400 million public-private investment will establish up to 18 new clinical trial hubs across the UK to accelerate the development of new medicines.
The investment aims to enhance the UK's clinical trials infrastructure, improve patient recruitment, and provide researchers with access to advanced technology.

Bio-Path Holdings Advances in Clinical Trials and Expands into Obesity Treatment

Bio-Path Holdings, Inc. has made significant progress in its clinical trials for cancer treatments and is preparing to explore the use of its drug prexigebersen for obesity and obesity-related cancers. The company has developed molecular biomarkers to improve treatment outcomes and is advancing its DNAbilize platform across multiple indications.

Oleolive Receives NCI Grant to Study Propentofylline for Glioblastoma Treatment

Oleolive, Inc. has been awarded a $400,000 STTR grant from the National Cancer Institute to investigate propentofylline's potential in glioblastoma treatment.
Propentofylline, a repurposed drug, will be studied for its ability to enhance the chemosensitivity of glioblastoma tumor cells, potentially improving patient outcomes.

Reference News

[1]
Bio-Path Holdings Advances Clinical Trials and Secures $4 Million in Funding - citybuzz -
citybuzz.co · Dec 29, 2024

Bio-Path Holdings advances in cancer treatment trials, secures $4M funding. Lead candidate prexigebersen progresses in P...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy